Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bloomberg Natural Gas ETF vs Danaher Corporation — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $20.92, while Danaher Corporation trades at $205.56 (market cap $145.83B). The key difference: Danaher Corporation pays a 0.77% dividend while ProShares Ultra Bloomberg Natural Gas ETF pays none, and Danaher Corporation is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BOIL | DHR | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $87.24 | $242.05 |
52-Week Low | $18.74 | $161.91 |
Market Cap | — | $145.83B |
Enterprise Value | — | $168.04B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOIL trades at $21.085, up 1.81% in the last 24 hours, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights U.S. natural gas futures stability amid weather-driven demand shifts. The company, Beyond Oil Ltd., focuses on food-tech innovations to reduce health risks in fried foods, with recent corporate actions including a 1:2 stock split effective May 28, 2026.
The outlook for BOIL is cautious due to bearish technical trends and reliance on natural gas market volatility. Investment opportunities hinge on energy sector demand and company-specific growth in food-tech, while risks include commodity price swings and execution challenges in scaling innovations.
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
